Literature DB >> 15282535

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.

Nelson J Chao1, Liang-Piu Koh, Gwynn D Long, Cristina Gasparetto, Mitchell Horwitz, Ashley Morris, Martha Lassiter, Keith M Sullivan, David A Rizzieri.   

Abstract

We report the outcome of 13 patients with advanced malignancies who underwent nonmyeloablative conditioning therapy followed by infusion of partially matched unrelated cord blood cells. The median age of these patients was 49 years, and their median weight was 65.7 kg. The median nucleated cell dose infused was 2.07 x 10(7)/kg. Eight of the 13 patients demonstrated donor chimerism between 4 weeks and 6 months, and subsequent conversion to full donor chimerism was achieved in 5 patients. Three patients were alive and free of disease at 158 to 1054 days, with a median survival of 288 days after transplantation. The 100-day event-free survival is 69%, and overall survival is 77%. At 1 year, the event-free and overall survival was 43%. Treatment-related mortality observed within the first 100 days after transplantation was low: 1 previously extensively pretreated patient died of multiorgan failure. This result provides a basis for further exploring this potentially curative approach to selected patients who lack matched related or unrelated hematopoietic stem cell donors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282535     DOI: 10.1016/j.bbmt.2004.05.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  13 in total

1.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

2.  Evaluation of Quality Parameters for Cord Blood Donations.

Authors:  Ursula Salge-Bartels; Helga Marie Huber; Kornelia Kleiner; Peter Volkers; Rainer Seitz; Margarethe Heiden
Journal:  Transfus Med Hemother       Date:  2009-08-21       Impact factor: 3.747

3.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

Review 4.  Umbilical cord blood transplantation.

Authors:  Demetrios Petropoulos; Ka Wah Chan
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

Review 5.  Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood.

Authors:  Joanne Kurtzberg; Anne Drapkin Lyerly; Jeremy Sugarman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 6.  The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.

Authors:  Corey Cutler; Joseph H Antin
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

7.  Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.

Authors:  Mahito Misawa; Shunro Kai; Masaya Okada; Toshiyuki Nakajima; Kaori Nomura; Takeshi Wakae; Akinari Toda; Hisayuki Itoi; Hiroyuki Takatsuka; Takeyoshi Itsukuma; Keisuke Nishioka; Yoshihiro Fujimori; Hiroyasu Ogawa; Hiroshi Hara
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

8.  Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.

Authors:  F Ostronoff; F Milano; T Gooley; J A Gutman; P McSweeney; F B Petersen; B M Sandmaier; R Storb; C Delaney
Journal:  Bone Marrow Transplant       Date:  2012-12-17       Impact factor: 5.483

9.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

10.  A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

Authors:  M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki
Journal:  Bone Marrow Transplant       Date:  2014-04-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.